500 related articles for article (PubMed ID: 18294023)
1. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies.
Wilcock GK; Ballard CG; Cooper JA; Loft H
J Clin Psychiatry; 2008 Mar; 69(3):341-8. PubMed ID: 18294023
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind, placebo-controlled trial of memantine in a behaviorally enriched sample of patients with moderate-to-severe Alzheimer's disease.
Herrmann N; Gauthier S; Boneva N; Lemming OM;
Int Psychogeriatr; 2013 Jun; 25(6):919-27. PubMed ID: 23472619
[TBL] [Abstract][Full Text] [Related]
3. Changes in nursing burden following memantine for agitation and aggression in long-term care residents with moderate to severe Alzheimer's disease: an open-label pilot study.
Herrmann N; Cappell J; Eryavec GM; Lanctôt KL
CNS Drugs; 2011 May; 25(5):425-33. PubMed ID: 21476613
[TBL] [Abstract][Full Text] [Related]
4. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis.
Gauthier S; Loft H; Cummings J
Int J Geriatr Psychiatry; 2008 May; 23(5):537-45. PubMed ID: 18058838
[TBL] [Abstract][Full Text] [Related]
5. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment.
Cummings JL; Schneider E; Tariot PN; Graham SM;
Neurology; 2006 Jul; 67(1):57-63. PubMed ID: 16832078
[TBL] [Abstract][Full Text] [Related]
6. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
Tariot PN; Farlow MR; Grossberg GT; Graham SM; McDonald S; Gergel I;
JAMA; 2004 Jan; 291(3):317-24. PubMed ID: 14734594
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the efficacy of pimavanserin in the treatment of agitation and aggression in patients with Alzheimer's disease psychosis: A post hoc analysis.
Ballard CG; Coate B; Abler V; Stankovic S; Foff E
Int J Geriatr Psychiatry; 2020 Nov; 35(11):1402-1408. PubMed ID: 32729631
[TBL] [Abstract][Full Text] [Related]
8. A double-blind randomized placebo-controlled withdrawal trial comparing memantine and antipsychotics for the long-term treatment of function and neuropsychiatric symptoms in people with Alzheimer's disease (MAIN-AD).
Ballard C; Thomas A; Gerry S; Yu LM; Aarsland D; Merritt C; Corbett A; Davison C; Sharma N; Khan Z; Creese B; Loughlin P; Bannister C; Burns A; Win SN; Walker Z;
J Am Med Dir Assoc; 2015 Apr; 16(4):316-22. PubMed ID: 25523285
[TBL] [Abstract][Full Text] [Related]
9. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.
De Deyn PP; Katz IR; Brodaty H; Lyons B; Greenspan A; Burns A
Clin Neurol Neurosurg; 2005 Oct; 107(6):497-508. PubMed ID: 15922506
[TBL] [Abstract][Full Text] [Related]
10. A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil.
van Dyck CH; Schmitt FA; Olin JT;
Am J Geriatr Psychiatry; 2006 May; 14(5):428-37. PubMed ID: 16670247
[TBL] [Abstract][Full Text] [Related]
11. The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitors.
Grossberg GT; Manes F; Allegri RF; Gutiérrez-Robledo LM; Gloger S; Xie L; Jia XD; Pejović V; Miller ML; Perhach JL; Graham SM
CNS Drugs; 2013 Jun; 27(6):469-78. PubMed ID: 23733403
[TBL] [Abstract][Full Text] [Related]
12. Memantine ER Maintains Patient Response in Moderate to Severe Alzheimer's Disease: Post Hoc Analyses From a Randomized, Controlled, Clinical Trial of Patients Treated With Cholinesterase Inhibitors.
Grossberg GT; Alva G; Hendrix S; Ellison N; Kane MC; Edwards J
Alzheimer Dis Assoc Disord; 2018; 32(3):173-178. PubMed ID: 29771687
[TBL] [Abstract][Full Text] [Related]
13. Randomized Placebo-Controlled Trial of Nabilone for Agitation in Alzheimer's Disease.
Herrmann N; Ruthirakuhan M; Gallagher D; Verhoeff NPLG; Kiss A; Black SE; Lanctôt KL
Am J Geriatr Psychiatry; 2019 Nov; 27(11):1161-1173. PubMed ID: 31182351
[TBL] [Abstract][Full Text] [Related]
14. Memantine for dementia.
Areosa SA; Sherriff F
Cochrane Database Syst Rev; 2003; (3):CD003154. PubMed ID: 12917950
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of memantine for agitation in Alzheimer's dementia: a randomised double-blind placebo controlled trial.
Fox C; Crugel M; Maidment I; Auestad BH; Coulton S; Treloar A; Ballard C; Boustani M; Katona C; Livingston G
PLoS One; 2012; 7(5):e35185. PubMed ID: 22567095
[TBL] [Abstract][Full Text] [Related]
16. Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials.
Winblad B; Jones RW; Wirth Y; Stöffler A; Möbius HJ
Dement Geriatr Cogn Disord; 2007; 24(1):20-7. PubMed ID: 17496417
[TBL] [Abstract][Full Text] [Related]
17. The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease.
Clark WS; Street JS; Feldman PD; Breier A
J Clin Psychiatry; 2001 Jan; 62(1):34-40. PubMed ID: 11235926
[TBL] [Abstract][Full Text] [Related]
18. Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies.
Gauthier S; Wirth Y; Möbius HJ
Int J Geriatr Psychiatry; 2005 May; 20(5):459-64. PubMed ID: 15852444
[TBL] [Abstract][Full Text] [Related]
19. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia.
Brodaty H; Ames D; Snowdon J; Woodward M; Kirwan J; Clarnette R; Lee E; Lyons B; Grossman F
J Clin Psychiatry; 2003 Feb; 64(2):134-43. PubMed ID: 12633121
[TBL] [Abstract][Full Text] [Related]
20. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease.
Wilkinson D; Andersen HF
Dement Geriatr Cogn Disord; 2007; 24(2):138-45. PubMed ID: 17622761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
